

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CPlus
NEWS 6	May 27	CPlus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CPlus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:54:23 ON 18 AUG 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:54:32 ON 18 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 AUG 2004 HIGHEST RN 727974-89-2

DICTIONARY FILE UPDATES: 17 AUG 2004 HIGHEST RN 727974-89-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10736243.1

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 CH,NH

*Handwritten signature: M. J. S.*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 10:55:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 109 TO ITERATE

100.0% PROCESSED 109 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 10:55:05 ON 18 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Aug 2004 VOL 141 ISS 8

FILE LAST UPDATED: 17 Aug 2004 (20040817/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 1 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:539677 CAPLUS

DN 137:109202

TI Preparation of 4-aryl substituted indolinones as protein kinase signal transduction modulators for inhibiting abnormal cell proliferation

IN Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho

PA USA

SO PCT Int. Appl., 560 pp.

CODEN: PIXXD2


DT Patent

LA English

## FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055517	A2	20020718	WO 2001-US48564	20011220
	WO 2002055517	A3	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003069297	A1	20030410	US 2000-256479P	P 20001220
	US 6677368	B2	20040113	US 2001-23488	20011220
				US 2000-256479P	P 20001220
EP	1349852	A2	20031008	EP 2001-997065	20011220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-256479P	P 20001220
				WO 2001-US48564	W 20011220
JP	2004518669	T2	20040624	JP 2002-556186	20011220
				US 2000-256479P	P 20001220
				WO 2001-US48564	W 20011220
US	2004157909	A1	20040812	US 2003-736243	20031216
				US 2000-256479P	P 20001220
				US 2001-23488	A3 20011220
OS	MARPAT 137:109202				
IT	<b>442559-47-9P 442559-48-0P</b>				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)				
RN	442559-47-9 CAPLUS				
CN	2H-Indol-2-one, 4-(2-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)				


Double bond geometry as shown.




RN 442559-48-0 CAPLUS

CN 2H-Indol-2-one, 4-(3-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



GI



I



II

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepared and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepared via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specific kinases, e.g., FGFR1, for which I possessed IC50 values ( $\mu$ M) of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CPlus
NEWS	6	May 27 CPlus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 CPlus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:17:05 ON 18 AUG 2004

=> fdile reg

FDILE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND  
command can only be used to look at the index in a file which has an  
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of  
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 11:18:13 ON 18 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 AUG 2004 HIGHEST RN 727974-89-2

DICTIONARY FILE UPDATES: 17 AUG 2004 HIGHEST RN 727974-89-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10736243.2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 CH,NH

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1 sss full

FULL SEARCH INITIATED 11:18:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3216 TO ITERATE

100.0% PROCESSED 3216 ITERATIONS

498 ANSWERS

SEARCH TIME: 00.00.01

L2 498 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.84

FILE 'CAPLUS' ENTERED AT 11:18:39 ON 18 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Aug 2004 VOL 141 ISS 8

FILE LAST UPDATED: 17 Aug 2004 (20040817/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 3 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:182368 CAPLUS

DN 140:229401

TI Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands

IN Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph

PA USA

SO U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004043388	A1	20040304	US 2002-234985	20020903
				US 2001-272932P	P 20010302
				US 2001-278233P	P 20010323
				US 2001-329437P	P 20011015
				US 2002-91177	A2 20020304
	US 2003165873	A1	20030904	US 2002-91177	20020304
				US 2001-272932P	P 20010302
				US 2001-278233P	P 20010323
				US 2001-329437P	P 20011015


PATENT FAMILY INFORMATION:

FAN 2002:696096

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070662	A2	20020912	WO 2002-US6677	20020304
	WO 2002070662	A3	20021227		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-272932P	P 20010302
				US 2001-278233P	P 20010323
				US 2001-329437P	P 20011015
EP 1364212		A2	20031126	EP 2002-723332	20020304
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2001-272932P	P 20010302
				US 2001-278233P	P 20010323
				US 2001-329437P	P 20011015
				WO 2002-US6677	W 20020304

FAN 2003:319902

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033499	A2	20030424	WO 2002-US33052	20021015
	WO 2003033499	A3	20030814		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-329437P	P 20011015
				US 2001-336962P	P 20011203
EP	1446405	A2	20040818	EP 2002-797047	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-329437P	P 20011015
				US 2001-336962P	P 20011203
				WO 2002-US33052	W 20021015
US	2003162797	A1	20030828	US 2002-321284	20021217
US	6753329	B2	20040622		
				US 2001-336962P	P 20011203
				WO 2002-US33052	A1 20021015
IT	<b>666838-05-7D</b> , conjugates				
	RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)				
RN	666838-05-7 CAPLUS				
CN	2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-(9CI) (CA INDEX NAME)				



AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:539677 CAPLUS

DN 137:109202

TI Preparation of 4-aryl substituted indolinones as protein kinase signal

transduction modulators for inhibiting abnormal cell proliferation  
 IN Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie;  
 Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng  
 Cho  
 PA USA  
 SO PCT Int. Appl., 560 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055517	A2	20020718	WO 2001-US48564	20011220
	WO 2002055517	A3	20020926		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003069297	A1	20030410	US 2000-256479P	P 20001220
	US 6677368	B2	20040113	US 2001-23488	20011220
				US 2000-256479P	P 20001220
EP	1349852	A2	20031008	EP 2001-997065	20011220
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-256479P	P 20001220
				WO 2001-US48564	W 20011220
JP	2004518669	T2	20040624	JP 2002-556186	20011220
				US 2000-256479P	P 20001220
				WO 2001-US48564	W 20011220
US	2004157909	A1	20040812	US 2003-736243	20031216
				US 2000-256479P	P 20001220
				US 2001-23488	A3 20011220

OS MARPAT 137:109202


IT **442563-63-5**

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of (aryl) (pyrrolylmethylene)indolinones as protein kinase  
 signal transduction modulators)

RN 442563-63-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-  
 3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 442558-03-4P 442558-04-5P 442558-05-6P  
442558-06-7P 442558-07-8P 442558-08-9P  
442558-09-0P 442558-10-3P 442558-11-4P  
442558-12-5P 442558-13-6P 442558-14-7P  
442558-15-8P 442558-16-9P 442558-17-0P  
442558-18-1P 442558-19-2P 442558-20-5P  
442558-21-6P 442558-22-7P 442558-23-8P  
442558-24-9P 442558-25-0P 442558-26-1P  
442558-27-2P 442558-28-3P 442558-29-4P  
442558-30-7P 442558-31-8P 442558-32-9P  
442558-33-0P 442558-34-1P 442558-35-2P  
442558-36-3P 442558-37-4P 442558-38-5P  
442558-39-6P 442558-40-9P 442558-41-0P  
442558-42-1P 442558-43-2P 442558-44-3P  
442558-45-4P 442558-46-5P 442558-47-6P  
442558-48-7P 442558-49-8P 442558-50-1P  
442558-51-2P 442558-52-3P 442558-53-4P  
442558-54-5P 442558-55-6P 442558-56-7P  
442558-57-8P 442558-58-9P 442558-59-0P  
442558-60-3P 442558-61-4P 442558-62-5P  
442558-63-6P 442558-64-7P 442558-65-8P  
442558-66-9P 442558-67-0P 442558-68-1P  
442558-69-2P 442558-70-5P 442558-71-6P  
442558-72-7P 442558-73-8P 442558-74-9P  
442558-75-0P 442558-76-1P 442558-77-2P  
442558-78-3P 442558-79-4P 442558-80-7P  
442558-81-8P 442558-82-9P 442558-83-0P  
442558-84-1P 442558-85-2P 442558-86-3P  
442558-87-4P 442558-88-5P 442558-89-6P  
442558-90-9P 442558-91-0P 442558-92-1P  
442558-93-2P 442558-94-3P 442558-95-4P  
442558-96-5P 442558-97-6P 442558-98-7P  
442558-99-8P 442559-00-4P 442559-01-5P  
442559-02-6P 442559-03-7P 442559-04-8P  
442559-05-9P 442559-06-0P 442559-07-1P  
442559-08-2P 442559-09-3P 442559-10-6P  
442559-11-7P 442559-12-8P 442559-14-0P  
442559-15-1P 442559-16-2P 442559-19-5P  
442559-20-8P 442559-21-9P 442559-22-0P  
442559-23-1P 442559-24-2P 442559-25-3P  
442559-26-4P 442559-27-5P 442559-28-6P  
442559-29-7P 442559-30-0P 442559-31-1P  
442559-32-2P 442559-41-3P 442559-42-4P  
442559-43-5P 442559-44-6P 442559-45-7P  
442559-46-8P 442559-47-9P 442559-48-0P


442559-49-1P 442559-50-4P 442559-51-5P  
 442559-52-6P 442559-53-7P 442559-54-8P  
 442559-55-9P 442559-56-0P 442559-57-1P  
 442559-58-2P 442559-59-3P 442559-60-6P  
 442559-61-7P 442559-62-8P 442559-63-9P  
 442559-64-0P 442559-65-1P 442559-66-2P  
 442559-67-3P 442559-68-4P 442559-69-5P  
 442559-70-8P 442559-71-9P 442559-72-0P  
 442559-73-1P 442559-74-2P 442559-75-3P  
 442559-76-4P 442559-77-5P 442559-78-6P  
 442559-79-7P 442559-80-0P 442559-81-1P  
 442559-82-2P 442559-83-3P 442559-84-4P  
 442559-85-5P 442559-86-6P 442559-87-7P  
 442559-88-8P 442559-89-9P 442559-90-2P  
 442559-91-3P 442559-92-4P 442559-93-5P  
 442559-94-6P 442559-95-7P 442559-96-8P  
 442559-97-9P 442559-98-0P 442559-99-1P  
 442560-00-1P 442560-01-2P 442560-02-3P  
 442560-03-4P 442560-04-5P 442560-05-6P  
 442560-06-7P 442560-07-8P 442560-08-9P  
 442560-09-0P 442560-10-3P 442560-11-4P  
 442560-12-5P 442560-13-6P 442560-14-7P  
 442560-15-8P 442560-16-9P 442560-17-0P  
 442560-18-1P 442560-19-2P 442560-20-5P  
 442560-21-6P 442560-22-7P 442560-23-8P  
 442560-24-9P 442560-25-0P 442560-26-1P  
 442560-27-2P 442560-28-3P 442560-29-4P  
 442560-30-7P 442560-31-8P 442560-32-9P  
 442560-33-0P 442560-34-1P 442560-35-2P  
 442560-36-3P 442560-37-4P 442560-38-5P  
 442560-39-6P 442560-40-9P 442560-41-0P  
 442560-42-1P 442560-43-2P 442560-44-3P  
 442560-45-4P 442560-46-5P 442560-47-6P  
 442560-48-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442558-03-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-4-phenyl-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



AN 2000:421132 CAPLUS  
DN 133:43433  
TI Preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of  
JNK protein kinases.  
IN Corbett, Wendy Lea; Luk, Kin-chun; Mahaney, Paige E.  
PA F. Hoffmann-La Roche A.-G., Switz.  
SO PCT Int. Appl., 91 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000035909	A1	20000622	WO 1999-EP9673	19991209
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				

Patel

<8/18/2004>

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
BR 9916223	A	20010904	BR 1999-16223		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
EP 1149093	A1	20011031	EP 1999-966933		19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
TR 200101858	T2	20011221	TR 2001-200101858		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
AU 760039	B2	20030508	AU 2000-22815		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
CN 1136216	B	20040128	CN 1999-814585		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
US 6307056	B1	20011023	US 1999-464466		19991215
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
ZA 2001004320	A	20020826	ZA 2001-4320		20010525
			US 1998-112590P	P	19981217

OS MARPAT 133:43433


IT 276250-95-4P 276250-97-6P 276250-98-7P  
276250-99-8P 276251-00-4P 276251-02-6P  
276251-04-8P 276251-06-0P 276251-08-2P  
276251-10-6P 276251-12-8P 276251-14-0P  
276251-16-2P 276251-18-4P 276251-19-5P  
276251-20-8P 276251-21-9P 276251-22-0P  
276251-23-1P 276251-24-2P 276251-25-3P  
276251-26-4P 276251-27-5P 276251-28-6P  
276251-29-7P 276251-30-0P 276251-31-1P  
276251-32-2P 276251-33-3P 276251-35-5P  
276251-36-6P 276251-37-7P 276251-38-8P  
276251-39-9P 276251-40-2P 276251-41-3P  
276251-42-4P 276251-43-5P 276251-44-6P  
276251-45-7P 276251-46-8P 276251-47-9P  
276251-48-0P 276251-49-1P 276251-50-4P  
276251-51-5P 276251-52-6P 276251-67-3P  
276251-68-4P 276251-69-5P 276251-70-8P  
276256-00-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276250-95-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-phenyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-  
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276250-97-6 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276250-98-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 276250-99-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-00-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(3-nitrophenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-02-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-4-[3-(trifluoromethyl)phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 276251-04-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-

, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-06-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-08-2 CAPLUS

CN 2H-Indol-2-one, 4-(2,4-dichlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-10-6 CAPLUS

CN Methanesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-12-8 CAPLUS

CN 2H-Indol-2-one, 4-(4-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-14-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-16-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1-naphthalenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-18-4 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-19-5 CAPLUS

CN 2H-Indol-2-one, 4-(3-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-20-8 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-21-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-22-0 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-23-1 CAPLUS

CN Benzamide, 3-bromo-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-24-2 CAPLUS

CN Benzamide, 3-cyano-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-25-3 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-26-4 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-27-5 CAPLUS

Benzamide, N-3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-28-6 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-29-7 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-30-0 CAPLUS

CN Benzoic acid, 3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-31-1 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[[2-[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-32-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-33-3 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-35-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-36-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-37-7 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-38-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-39-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-40-2 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-41-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-42-4 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-43-5 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-44-6 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-45-7 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,5'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-46-8 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-47-9 CAPLUS

CN Benzoic acid, 4-[(3Z)-5-amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-48-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-4-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-49-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-50-4 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,6'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-51-5 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-52-6 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-67-3 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-68-4 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-69-5 CAPLUS

CN Acetamide, 2-[[3-[(3Z)-5-fluoro-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]phenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-70-8 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-[4-(hydroxymethyl)-3-methoxyphenyl]-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276256-00-9 CAPLUS

CN Cyclohexanecarboxamide, 4-amino-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 276251-76-4P 276251-79-7P 276251-80-0P

276251-81-1P 276251-82-2P 276256-01-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276251-76-4 CAPLUS

CN Carbamic acid, [3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-79-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-80-0 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-81-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-82-2 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 276256-01-0 CAPLUS

CN Carbamic acid, [4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl,

etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 µM.

RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
BR 9916223	A	20010904	BR 1999-16223		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
EP 1149093	A1	20011031	EP 1999-966933		19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
TR 200101858	T2	20011221	TR 2001-200101858		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
AU 760039	B2	20030508	AU 2000-22815		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
CN 1136216	B	20040128	CN 1999-814585		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
US 6307056	B1	20011023	US 1999-464466		19991215
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
ZA 2001004320	A	20020826	ZA 2001-4320		20010525
			US 1998-112590P	P	19981217

OS MARPAT 133:43433


IT 276250-95-4P 276250-97-6P 276250-98-7P  
276250-99-8P 276251-00-4P 276251-02-6P  
276251-04-8P 276251-06-0P 276251-08-2P  
276251-10-6P 276251-12-8P 276251-14-0P  
276251-16-2P 276251-18-4P 276251-19-5P  
276251-20-8P 276251-21-9P 276251-22-0P  
276251-23-1P 276251-24-2P 276251-25-3P  
276251-26-4P 276251-27-5P 276251-28-6P  
276251-29-7P 276251-30-0P 276251-31-1P  
276251-32-2P 276251-33-3P 276251-35-5P  
276251-36-6P 276251-37-7P 276251-38-8P  
276251-39-9P 276251-40-2P 276251-41-3P  
276251-42-4P 276251-43-5P 276251-44-6P  
276251-45-7P 276251-46-8P 276251-47-9P  
276251-48-0P 276251-49-1P 276251-50-4P  
276251-51-5P 276251-52-6P 276251-67-3P  
276251-68-4P 276251-69-5P 276251-70-8P  
276256-00-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276250-95-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-phenyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-  
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276250-97-6 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276250-98-7 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 276250-99-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-00-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(3-nitrophenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-02-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-4-[3-(trifluoromethyl)phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 276251-04-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-

, (3Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-06-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-08-2 CAPLUS

CN 2H-Indol-2-one, 4-(2,4-dichlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-10-6 CAPLUS

CN Methanesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-12-8 CAPLUS

CN 2H-Indol-2-one, 4-(4-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-14-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-16-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1-naphthalenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-18-4 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-19-5 CAPLUS

CN 2H-Indol-2-one, 4-(3-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-20-8 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-21-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-((3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-22-0 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-23-1 CAPLUS

CN Benzamide, 3-bromo-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-24-2 CAPLUS

CN Benzamide, 3-cyano-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-25-3 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-26-4 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-27-5 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-28-6 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-29-7 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-30-0 CAPLUS

CN Benzoic acid, 3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-31-1 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[[2-[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-32-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-33-3 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-35-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-36-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-37-7 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-38-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-39-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-40-2 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-41-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-42-4 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-43-5 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-44-6 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-45-7 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,5'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-46-8 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-47-9 CAPLUS

CN Benzoic acid, 4-[(3Z)-5-amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-48-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-4-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-49-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-50-4 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,6'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-51-5 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-52-6 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-67-3 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-68-4 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-69-5 CAPLUS

CN Acetamide, 2-[[3-[(3Z)-5-fluoro-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]phenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-70-8 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-[4-(hydroxymethyl)-3-methoxyphenyl]-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276256-00-9 CAPLUS

CN Cyclohexanecarboxamide, 4-amino-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 276251-76-4P 276251-79-7P 276251-80-0P  
 276251-81-1P 276251-82-2P 276256-01-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of  
 JNK protein kinases)

RN 276251-76-4 CAPLUS

CN Carbamic acid, [3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-  
 indol-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-79-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-  
 yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-80-0 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-81-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-82-2 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 276256-01-0 CAPLUS

CN Carbamic acid, [4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl,

etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 µM.

RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
BR 9916223	A	20010904	BR 1999-16223		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
EP 1149093	A1	20011031	EP 1999-966933		19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
TR 200101858	T2	20011221	TR 2001-200101858		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
AU 760039	B2	20030508	AU 2000-22815		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
CN 1136216	B	20040128	CN 1999-814585		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
US 6307056	B1	20011023	US 1999-464466		19991215
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
ZA 2001004320	A	20020826	ZA 2001-4320		20010525
			US 1998-112590P	P	19981217

OS MARPAT 133:43433  
IT 276250-95-4P 276250-97-6P 276250-98-7P  
276250-99-8P 276251-00-4P 276251-02-6P  
276251-04-8P 276251-06-0P 276251-08-2P  
276251-10-6P 276251-12-8P 276251-14-0P  
276251-16-2P 276251-18-4P 276251-19-5P  
276251-20-8P 276251-21-9P 276251-22-0P  
276251-23-1P 276251-24-2P 276251-25-3P  
276251-26-4P 276251-27-5P 276251-28-6P  
276251-29-7P 276251-30-0P 276251-31-1P  
276251-32-2P 276251-33-3P 276251-35-5P  
276251-36-6P 276251-37-7P 276251-38-8P  
276251-39-9P 276251-40-2P 276251-41-3P  
276251-42-4P 276251-43-5P 276251-44-6P  
276251-45-7P 276251-46-8P 276251-47-9P  
276251-48-0P 276251-49-1P 276251-50-4P  
276251-51-5P 276251-52-6P 276251-67-3P  
276251-68-4P 276251-69-5P 276251-70-8P  
276256-00-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276250-95-4 CAPLUS  
CN 2H-Indol-2-one, 1,3-dihydro-4-phenyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-  
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276250-97-6 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276250-98-7 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 276250-99-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-00-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(3-nitrophenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-02-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-4-[3-(trifluoromethyl)phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 276251-04-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-

, (3Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-06-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-08-2 CAPLUS

CN 2H-Indol-2-one, 4-(2,4-dichlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-10-6 CAPLUS

CN Methanesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-12-8 CAPLUS

CN 2H-Indol-2-one, 4-(4-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-14-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-16-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1-naphthalenyl)-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-18-4 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-19-5 CAPLUS

CN 2H-Indol-2-one, 4-(3-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-  
, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-20-8 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-21-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-22-0 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-23-1 CAPLUS

CN Benzamide, 3-bromo-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-24-2 CAPLUS

CN Benzamide, 3-cyano-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-25-3 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-26-4 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-27-5 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-28-6 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-29-7 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-30-0 CAPLUS

CN Benzoic acid, 3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-31-1 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[[2-[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-32-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-33-3 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-35-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-36-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-37-7 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-38-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-39-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-40-2 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-41-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-42-4 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-43-5 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-44-6 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-45-7 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,5'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-46-8 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-47-9 CAPLUS

CN Benzoic acid, 4-[(3Z)-5-amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-48-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-4-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-49-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-50-4 CAPLUS

CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,6'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-51-5 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-52-6 CAPLUS

CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-67-3 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-68-4 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-69-5 CAPLUS

CN Acetamide, 2-[[[3-[(3Z)-5-fluoro-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]phenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-70-8 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-[4-(hydroxymethyl)-3-methoxyphenyl]-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276256-00-9 CAPLUS

CN Cyclohexanecarboxamide, 4-amino-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 276251-76-4P 276251-79-7P 276251-80-0P  
 276251-81-1P 276251-82-2P 276256-01-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of  
 JNK protein kinases)

RN 276251-76-4 CAPLUS

CN Carbamic acid, [3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-  
 indol-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-79-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-  
 yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-80-0 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-81-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 276251-82-2 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 276256-01-0 CAPLUS

CN Carbamic acid, [4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl,

etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 µM.

RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT